Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Results for New Oxazolidinone Demonstrate Potency Against Superbugs

08.01.2002


Results for New Oxazolidinone Demonstrate Potency Against Gram-Positive Pathogens, including Superbugs



Unique compound AZD2563 shows promise for once-daily dosing

Chicago, IL World-wide data presented at the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC) show that AstraZeneca`s new oxazolidinone (AZD2563) is active against Gram-positive bacteria, including multi-drug resistant strains, and may have the added convenience of potential once-daily administration. In addition, the compound is more potent in vitro than linezolid, the only oxazolidinone currently on the market.


AZD2563 is the latest oxazolidinone under early-stage development for the treatment of infection with Gram-positive bacteria, including multiple-drug resistant strains. The promising novel oxazolidinone compound is being developed by AstraZeneca, and its microbiological data have been proven world-wide.

A major public health threat is posed by strains of Gram-positive bacteria that have evolved resistance to treatment: some are now resistant to many common antibiotics Overcoming Antimicrobial Resistance. (World Health Report on Infectious Diseases 2000. WHO, 2000.) Some only respond to recently developed intravenous anti-bacterials, or physicians have to rely on older and potentially more toxic drugs. Oxazolidinones are a new class of antibiotics with a novel mode of action and proven world-wide clinical data that meet the urgent need for new therapies for a spectrum of Gram-positive infections, including multiple-drug resistant strains.

Keith Williams, Global Product Director at AstraZeneca, said "Seventeen abstracts were selected for presentation at ICAAC. These contain important new data that suggest the unique structure of AZD2563 confers potency and potential once-daily dosing. It appears likely that AZD2563 will have a vital role to play in the fight against Gram-positive infections."

These initial results indicate that AZD2563 has excellent, targeted activity against all common Gram-positive bacteria, regardless of resistance to other classes of antibiotics. In one study (Turner PJ, Wookey A, Greenhalgh JM, Eastwood M, Clarke J. Investigations into the Antibacterial Spectrum of the New Oxazolidinone AZD2563. Poster presented at ICAAC 2001. Abstract F-1024.), the effectiveness of AZD2563 was measured against 838 clinical strains of bacteria, and its level of activity was compared to 14 antibiotics, including linezolid. Principal Investigator Dr Philip Turner commented: "For the majority of strains of streptococci and staphylococci, including methicillin-resistant staphylococci, AZD2563 was more potent in vitro than linezolid. Activities against strains of enterococci and pneumococci were comparable between AZD2563 and linezolid. Oxazolidinones are likely to evolve into a highly successful, widely-used class of antibiotics. AZD2563 will be available as an oral as well as an intravenous therapy and is a useful addition to the anti-Gram-positive armamentarium.”

Another study (Eliopoulis GM, Wennersten CB, Moellering Jr RC. Comparative In Vitro Activity of the New Oxazolidinone, AZD2563, against Enterococci. Poster presented at ICAAC 2001. Abstract F-1034). reinforces the suggestion that AZD2563 has a more powerful action than linezolid against some strains of bacteria. The activity of AZD2563 against 500 clinical isolates of enterococci was compared to linezolid and eight other antibiotics. The findings indicate that AZD2563 is generally two-fold more active in vitro than linezolid against enterococci, including multi-drug resistant strains. This suggests that AZD2563 is a potent oxazolidinone.

In addition, another study (Arundel PA. The New Oxazolidinone, AZD2563: Physiologically-based Pharmacokinetic Extrapolation to Man. Poster presented at ICAAC 2001. Abstract F-1039.) indicates that AZD2563 may offer the convenience of once-daily dosing. Currently, the only oxazolidinone on the market is indicated for twice-daily dosing in adults. In vivo data from AZD2563 were used to predict the behaviour of the compound in man. Human simulations based on experimental data predicted that AZD2563 is long-acting. Lead Investigator Dr Phil Arundel commented: "The fact that AZD2563 is long-acting and potent indicates that once-daily dosing is feasible. AZD2563 shows great promise in the fight against infections, including those caused by multi-drug resistant bacteria, and I await the results of further studies with interest".

Leslie Wheeler | alphagalileo

More articles from Health and Medicine:

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

nachricht ASU scientists develop new, rapid pipeline for antimicrobials
14.12.2017 | Arizona State University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

Im Focus: Successful Mechanical Testing of Nanowires

With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong

Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Plasmonic biosensors enable development of new easy-to-use health tests

14.12.2017 | Health and Medicine

New type of smart windows use liquid to switch from clear to reflective

14.12.2017 | Physics and Astronomy

BigH1 -- The key histone for male fertility

14.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>